Gemcitabine, Cisplatin, Nivolumab Facilitate Bladder Sparing

WEDNESDAY, Oct. 4, 2023 (HealthDay News) -- For patients with muscle-invasive bladder cancer (MIBC), treatment with gemcitabine, cisplatin, plus nivolumab facilitates bladder sparing, according to a study published online Oct. 2 in Nature Medicine.
Matthew D. Galsky, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues conducted a phase 2 study of 76 patients with MIBC who received four cycles of gemcitabine, cisplatin, plus nivolumab followed by clinical restaging. Patients who achieved a clinical complete response (cCR) could proceed without cystectomy.
Of the patients, 33 achieved a cCR (43 percent); 32 of the 33 opted to forgo immediate cystectomy. The researchers found that the positive predictive value of cCR for a composite outcome of two-year metastasis-free survival in patients forgoing immediate cystectomy or
"Treatment for muscle-invasive bladder cancer is in need of major improvements from both a quality-of-life and an effectiveness standpoint," Galsky said in a statement. "If additional research confirms our findings, this may lead to a new paradigm in the treatment of muscle-invasive bladder cancer."
Several authors disclosed ties to the biopharmaceutical and medical technology industries.
Related Posts
USPSTF Still Says Individualize Decision for Diet, Exercise Counseling
TUESDAY, July 26, 2022 (HealthDay News) -- The U.S Preventive Services Task...
Migraine May Raise Risk for Burning Mouth Syndrome
FRIDAY, April 29, 2022 (HealthDay News) -- Migraine is associated with an...
Subsequent Breast Cancer Risk Higher for Child Cancer Survivors Receiving Doxorubicin
TUESDAY, Sept. 19, 2023 (HealthDay News) -- For female survivors of childhood...
Beneficial Effects of Salt Substitutes on BP Are Consistent
WEDNESDAY, Aug. 10, 2022 (HealthDay News) -- The beneficial effects of salt...